AnPac Bio-Medical Science Co., Ltd. (ANPC) is a late-stage biopharmaceutical company engaged in the development of early cancer detection. The company has two authorized clinical labs including CLIA and CAP and performs Cancer Differentiation Analysis and another testing.
The price of ANPC stock during March 11, 2022, regular trading was $0.78 with an increase of 15.7%. At the last check of the aftermarket session, its price dipped by 19.9%.
ANPC: Events and Happenings
On March 11, 2022, ANPC announced the receipt of notification regarding non-compliance of the least bid price obligation from the Nasdaq Stock Market on March 8. The notification has no immediate effect on the company’s securities trading on the Nasdaq Capital Market. On March 03, 2022, ANPC reported that Changwei System Technology, its biochip subsidiary, was assessed by China Alliance Appraisal Co. Ltd.
On February 03, 2022, ANPC updated on filing a request regarding Breakthrough device designation for CDA technology-based device with the FDA on February 1. On January 25, 2022, ANPC informed the press about being ranked by the Frost & Sullivan Company as number one in the global multiple cancer detection volumes in its research report.
ANPC: Key Financials
On October 01, 2021, ANPC released its unaudited and consolidated financial statement for the first six months ended June 30, 2021. Some of the crucial points are discussed below.
Revenue
Total revenue in H1 2021 was RMB9.3 million compared to RMB4.1 million in the same half of 2020. The company reported a rise of 128.5% in its revenue YoY.
Net Loss
Net loss in H1 2021 was up to RMB57.7 million against RMB56.1 million in the same period in 2020. The company recorded an incline in its net loss YoY.
Conclusion
The stock price of ANPC down-performed in the past year as it fell by up to 90% as a result of the pandemic. Recently, its stock also dropped in the current aftermarket trading after the company issued non-compliance of minimum bid price notification from the NASDAQ.
